Dose Response


  • The average ED95 dose of NIMBEX is 0.05 mg/kg in patients receiving opioid/N2O/O2 anesthesia
  • In long surgical procedures with enflurane or isoflurane anesthesia, the effective dose of NIMBEX may be lower:
    • Less frequent maintenance dosing
    • Lower maintenance doses
    • Reduced infusion rates (as much as 30-40%)
  • Repeated dosing or continuous infusion of NIMBEX for up to 3 hours is not associated with:
    • Tachyphylaxis
    • Cumulative NMB effects
  • Recovery time from successive maintenance doses does not change with the number of doses administered as long as partial recovery is allowed to occur between doses1
  • The more profound the neuromuscular block at the time of reversal, the longer the time required for recovery of neuromuscular function1
Intubation Conditions


  • NIMBEX produced good or excellent tracheal intubation conditions within 1.5 minutes in: 
    •  94% of patients (0.15 mg/kg, 3 x ED95
    •  93% of patients (0.20 mg/kg, 4 x ED95
  • Results produced during adequate induction of anesthesia using propofol, nitrous oxide/oxygen, and co-induction agents (fentanyl and midazolam) 
  • NIMBEX has an intermediate onset of action and is not recommended for rapid sequence endotracheal intubation
  • NIMBEX should only be administered intravenously in carefully adjusted dosage by or under the supervision of experienced clinicians familiar with the drug’s actions and possible complications1

© 2022 AbbVie. All rights reserved.
ULTANE® and its design are registered trademarks of AbbVie Inc.
NIMBEX® and its design are registered trademarks of AbbVie Inc.
US-ANES-220003 November 2022

AbbVie logo